Compounds > azelastine

azelastine and losartan

azelastine has been researched along with losartan in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (75.00)29.6817
2010's0 (0.00)24.3611
2020's1 (25.00)2.80

Authors

AuthorsStudies
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL1
Lombardo, F; Obach, RS; Waters, NJ1
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV1
Ali, AA; Elnagar, GM; Elseweidy, MM; M Elsawy, M; Zein, N1

Other Studies

4 other study(ies) available for azelastine and losartan

ArticleYear
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
    Current drug discovery technologies, 2004, Volume: 1, Issue:4

    Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration

2004
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
    Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7

    Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding

2008
Physicochemical determinants of human renal clearance.
    Journal of medicinal chemistry, 2009, Aug-13, Volume: 52, Issue:15

    Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight

2009
Losartan and azelastine either alone or in combination as modulators for endothelial dysfunction and platelets activation in diabetic hyperlipidemic rats.
    The Journal of pharmacy and pharmacology, 2020, Volume: 72, Issue:12

    Topics: Alloxan; Angiotensin II Type 1 Receptor Blockers; Animals; Atherosclerosis; Blood Platelets; Diabetes Mellitus, Experimental; Drug Therapy, Combination; Endothelial Cells; Histamine H1 Antagonists, Non-Sedating; Hyperlipidemias; Hypolipidemic Agents; Losartan; Male; Phthalazines; Platelet Activation; Rats

2020